New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:06 EDTCCXIChemoCentryx CCX168 granted orphan designation in ANCA-associated diseases
ChemoCentryx confirmed that the FDA has granted orphan-drug designation for CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a. The designation is for the treatment of anti-neutrophil cytoplasmic autoantibodies, or ANCA, -associated vasculitides. CCX168 is currently in the third step of the CLEAR clinical trial in patients with ANCA-associated vasculitis. CEO Thomas Schall said, "We believe this designation may facilitate an expeditious clinical development path for CCX168, and is emblematic of our deep commitment to supporting the community of patients with ANCA-associated vasculitis."
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
16:31 EDTCCXIChemoCentryx grated FDA orphan-drug designation for CCX168
Subscribe for More Information
November 18, 2014
16:07 EDTCCXIChemoCentryx atypical hemolytic uremic syndrome treatment granted orphan status
Subscribe for More Information
November 17, 2014
08:52 EDTCCXIChemoCentryx reported additional data from CCX168 Phase II clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use